SAN FRANCISCO — They may be in the business of new life, but prenatal testing companies are fighting to the death in Northern District patent cases.
The brawl involves four life sciences companies, an army of elite lawyers, half a dozen patents and two high-profile universities. At stake, say those watching, is the future of non-invasive prenatal testing, which screens for genetic disorders using a mother’s blood sample, reducing the need for riskier procedures like amniocentesis.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
